Skip to main content

Table 1 Platelet desialylation of different groups [M (P 25, P 75)]

From: Platelet desialylation correlates with efficacy of first-line therapies for immune thrombocytopenia

 

Age

Gender (M/F)

PLT (×109/L)

RCA-1 (%)

ECL (%)

ITP (n = 61)

43 ± 18

18/43

16.0 ± 12.5

1.60 (0.50,8.50)

1.30 (0.30,5.05)

 Efficacy grouping (n = 61)

  CR (n = 26)

36 ± 16

4/22

16.1 ± 15.3

1.10 (0.30,2.05)

0.85 (0.28,1.90)

  R (n = 21)

44 ± 19

10/11

17.2 ± 10.5

1.80 (0.65,5.75)

1.00 (0.30,2.05)

  NR (n = 14)

52 ± 17

4/10

13.9 ± 9.7

32.95 (4.40,62.20)

20.60 (2.83,34.68)

 Antibody grouping (n = 33)

  Anti-GPIbα (+) (n = 9)

39 ± 14

2/7

10.7 ± 5.3

2.50 (0.55,24.15)

2.20 (0.45,13.85)

  Single anti-GPIIbIIIa (+) (n = 14)

35 ± 16

3/11

16.0 ± 14.5

0.55 (0.18,1.70)

0.35 (0.10,1.90)

  Double negative (n = 10)

41 ± 17

5/5

14.9 ± 9.7

0.65 (0.10,5.50)

1.15 (0.10,2.15)

CTD (n = 10)

43 ± 20

3/7

20.3 ± 20.0

5.15 (1.63,28.85)

2.20 (0.90,14.25)

MDS (n = 10)

51 ± 27

3/7

29.3 ± 18.4

8.75 (1.30,14.03)

5.60 (2.08,16.85)

AA (n = 6)

31 ± 11

4/2

28.2 ± 9.6

0.75 (0.18,18.3)

0.95 (0.10,3.05)

AML (n = 8)

49 ± 19

4/4

19.4 ± 18.6

0.20 (0.13,0.80)

0.03 (0.01,0.50)

Healthy control (n = 20)

41 ± 12

10/10

197.7 ± 61.7

0.10 (0.10,0.30)

0.00 (0.00,0.10)

  1. The platelets of primary ITP patients were collected prior to treatment. Fluorescin-conjugated lectins RCA-1 and ECL were used to detect desialylated galactose and β-GlcNAc residues on platelets via flow cytometry. Platelets from healthy blood donors (controls) and secondary ITP and non-ITP thrombocytopenic patients were also studied. Normal distribution measurement data is presented as mean ± SEM; skewed distribution measurement data is presented as M (P 25, P 75), in which M represents the median, P 25 and P 75 represent the 25th percentile and 75th percentile, respectively. Kruskal-Wallis rank sum test showed platelet desialylation is significantly higher in ITP patients as compared to that in healthy blood donors (RCA-1 Z = −4.918, p < 0.001; ECL Z = −5.512, p < 0.001). The course of therapies was independent from the platelet desialylation assays. The RCA-1 and ECL-positive platelets in non-responder (NR) group are significantly higher than those in complete responder (CR) and responder (R) groups (RCA-1 χ2 = 10.581, p < 0.01; ECL χ2 = 13.741, p < 0.005). No significant difference was observed between CR and R groups (p > 0.05). Correlation analysis indicated that as platelet desialylation increases, the efficacy of therapy decreases. Higher platelet desialylation in ITP patients with anti-GPIbα antibodies was observed as compared with other ITP patients although statistical difference was not reached (RCA-1 χ2 = 3.729, 0.16 > p > 0.05; ECL χ2 = 3.864, 0.15 > p > 0.05). Higher levels of platelet desialylation were also observed in patients of CTD (systemic lupus erythematosus, n = 6; sicca syndrome, n = 4) with thrombocytopenia; MDS and AA as compared with healthy controls (RCA-1 χ2 = 33.790, p < 0.001; ECL χ2 = 42.992, p < 0.001). There is no statistical difference in platelet desialylation between the AML patients and healthy donors (p > 0.05)
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us